![]() ![]() Infections: Serious infections have been reported.Anaphylaxis/hypersensitivity reactions: May cause rare hypersensitivity reactions discontinue use and initiate appropriate therapy if reaction occurs.Nervous system: Bacterial meningitis ( Streptococcus pneumoniae) Infection: Mycobacterium infection ( Mycobacterium intracellulare) ![]() Gastrointestinal: Colitis, gastrointestinal hemorrhage Hypersensitivity: Hypersensitivity reactionĮndocrine & metabolic: Increased HDL cholesterol, increased LDL cholesterol, increased serum cholesterol, increased serum triglycerides Respiratory: Upper respiratory tract infection (26%) Local: Injection site reaction (48% including bleeding at injection site, bruising at injection site, discomfort at injection site, erythema at injection site, inflammation at injection site, injection site blister formation, injection site pruritus, localized edema, pain at injection site, rash at injection site, residual mass at injection site, swelling at injection site, urticaria at injection site, warm sensation at injection site) Infection: Infection (34% to 48% including serious infection) Immunologic: Antibody development (35% neutralizing: 26%, no correlation of antibody activity was seen on clinical effectiveness or safety) ![]() The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Note: Do not administer more frequently than once weekly. Maintenance: SUBQ: Begin 1 week after loading dose: 160 mg once weekly. Initial: SUBQ: Loading dose: 320 mg given as 2 separate injections (160 mg each) on the same day at different sites. Maintenance dose: Begin 1 week after loading dose: SUBQ: 2.2 mg/kg/dose once weekly maximum dose: 160 mg/dose Note: Do not administer more frequently than once weekly maximum injection volume: 2 mL (160 mg) per injection. Initial: SUBQ: Loading dose: 4.4 mg/kg maximum dose: 320 mg/dose Note: Loading dose may be divided into 1 or 2 separate injections administered on same day at different sites maximum injection volume: 2 mL (160 mg) per injection. Pericarditis, recurrent: Note: In clinical trials, patients were weaned off their current standard pericarditis therapy (eg, NSAIDS, oral glucocorticoids, colchicine) over a 9-week period once rilonacept therapy initiated (Klein 2021).Ĭhildren ≥12 years and Adolescents ≤17 years: ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |